Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation

Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin lymphoma worldwide. Improved survival outcomes with rituximab-based therapy in clinical trials led to the establishment of rituximab-based immunochemotherapy as standard of care for first-line (1L) treatment of FL. In the GAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachy, Emmanuel, Rufibach, Kaspar, Parreira, Joana, Launonen, Aino, Nielsen, Tina, Hackshaw, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280048/
https://www.ncbi.nlm.nih.gov/pubmed/34041708
http://dx.doi.org/10.1007/s12325-021-01738-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280048/
https://www.ncbi.nlm.nih.gov/pubmed/34041708
http://dx.doi.org/10.1007/s12325-021-01738-2

Ejemplares similares